ストックスクリーナーアプリを入手
3.89
9.12%
0.325
アフターアワーズ：
3.90
0.010
+0.26%
前日終値:
$3.565
開ける：
$3.53
24時間の取引高:
2.23M
Relative Volume:
1.89
時価総額：
$324.46M
収益：
$13.86M
当期純損益:
$-81.74M
株価収益率:
-2.984
EPS:
-1.3036
ネットキャッシュフロー:
$-66.98M
1週間 パフォーマンス:
+20.43%
1か月 パフォーマンス:
+23.10%
6か月 パフォーマンス:
+161.07%
1年 パフォーマンス:
+141.61%
1日の値動き範囲:
$3.515
$4.05
1週間の範囲:
$3.0501
$4.05
52週間の値動き範囲:
$1.03
$5.55
Pyxis Oncology Inc Stock (PYXS) Company Profile
Compare PYXS vs VRTX, REGN, ARGX, MRNA, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PYXS
Pyxis Oncology Inc
|
3.89 | 260.23M | 13.86M | -81.74M | -66.98M | -1.3036 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Pyxis Oncology Inc Stock (PYXS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-11-03 | 再開されました | Stifel | Buy |
| 2025-09-04 | 開始されました | Guggenheim | Buy |
| 2024-11-21 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2024-11-08 | 開始されました | Stephens | Overweight |
| 2024-08-08 | 開始されました | Stifel | Buy |
| 2024-05-07 | 再開されました | Jefferies | Buy |
| 2024-02-09 | 開始されました | BTIG Research | Buy |
| 2024-01-23 | 開始されました | Leerink Partners | Outperform |
| 2023-09-05 | 開始されました | RBC Capital Mkts | Outperform |
| 2021-11-02 | 開始されました | BofA Securities | Neutral |
| 2021-11-02 | 開始されました | Credit Suisse | Outperform |
| 2021-11-02 | 開始されました | Jefferies | Buy |
すべてを表示
Pyxis Oncology Inc (PYXS) 最新ニュース
PYXS Rallies As Pyxis Oncology Extends Cash Runway To 2027 - timothysykes.com
PYXS Jumps As Pyxis Oncology Extends Cash Runway, Eyes MICVO Data - timothysykes.com
Pyxis Oncology stock gains on MICVO conference catalysts - AD HOC NEWS
Pyxis Oncology Inc (PYXS) Peer Comparison – Compare with Others - valueresearchonline.com
Pyxis Oncology Inc (PYXS) Key Financial Ratios – Valuation, Profitability & More - valueresearchonline.com
PYXS Stock Price, Quote & Chart - ChartMill
Pyxis Oncology to Participate in Upcoming Investor Conferences - GlobeNewswire
Pyxis Oncology Inc (PYXS) Shareholding Pattern – Promoters, FIIs & DIIs - valueresearchonline.com
Pyxis Oncology Inc (NASDAQ: PYXS) Share Price, PYXS Stock News, PYXS Share Price & Updates - kalkine.com.au
Pyxis Oncology files prospectus for 39.2M share sale by existing holders - scanx.trade
Pyxis Oncology (PYXS) awards director options at $3.12 - Stock Titan
Q3 EPS Estimates for Pyxis Oncology Raised by HC Wainwright - MarketBeat
Pyxis Oncology FY2030 EPS Forecast Reduced by HC Wainwright - MarketBeat
HC Wainwright Reiterates Buy Rating for Pyxis Oncology (NASDAQ:PYXS) - MarketBeat
symbol__ Stock Quote Price and Forecast - CNN
H.C. Wainwright Maintains Pyxis Oncology(PYXS.US) With Buy Rating, Maintains Target Price $7 - Moomoo
Pyxis Oncology (PYXS) Holds Steady at $3.01 as Consolidation TightensSign of Strength - siam.in
PYXS Q1 2026 Earnings: Modest EPS Beat Points to Cost Discipline for Clinical-Stage Oncology FirmDividend Earnings Report - vinanet.vn
Analysts Are Bullish on Top Healthcare Stocks: BridgeBio Pharma (BBIO), Pyxis Oncology (PYXS) - The Globe and Mail
Pyxis Oncology (PYXS) Gets a Buy from Wells Fargo - The Globe and Mail
Pyxis Oncology, Inc. (NASDAQ:PYXS) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Pyxis Oncology (PYXS) CEO receives 250,956-share performance-based option grant - Stock Titan
LifeSci Capital Maintains Pyxis Oncology(PYXS.US) With Buy Rating, Maintains Target Price $6 - Moomoo
Pyxis Oncology Faces Mounting Dilution Risk as Ongoing Equity Raises and Warrants Pressure Shareholder Value - TipRanks
Pyxis Oncology (NASDAQ:PYXS) Releases Quarterly Earnings Results, Misses Expectations By $0.06 EPS - MarketBeat
Pyxis Oncology Releases Q2 2026 Financial Results - AlphaStreet
Pyxis Oncology Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Pyxis Oncology Q2 loss widens 38%, misses EPS estimate - scanx.trade
Form 8K Pyxis Oncology Inc For: 13 August By Investing.com - Investing.com Nigeria
PYXS: MICVO demonstrates high efficacy and disease control in R/M HNSCC, with pivotal data due in 2026 - TradingView
Pyxis Oncology, Inc. Q2 2026: Revenue $0 EPS $(0.40) — 10-Q Summary - TradingView
Pyxis Oncology Reports $25.3 Million Second-Quarter Net Loss - Quiver Quantitative
Pyxis Oncology, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Pyxis Oncology Reports Second Quarter 2026 Financial Results and Advances MICVO Toward Key 2026 Clinical Milestones - The Manila Times
Pyxis Oncology 2Q Research and Development Expenses $16.1M >PYXS - Moomoo
Pyxis Oncology (PYXS) Rises 7.4% to $3.04 as Biotech Buying Momentum BuildsQuality Factor - Vinanet
currently "more than watching" heheheh - Moomoo
Pyxis Oncology Inc expected to post a loss of 35 cents a shareEarnings Preview - TradingView
Pyxis Oncology (PYXS) Gains 2.68% as Clinical-Stage Biotech Finds Buying SupportVolume Breakout Ideas - dars.gov.et
Pyxis Oncology Inc (PYXS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Pyxis Oncology Inc (PYXS) Stock News Today - TradingKey
Price to earnings forward of Pyxis Oncology, Inc. – NASDAQ:PYXS - TradingView
Price to sales forward of Pyxis Oncology, Inc. – NASDAQ:PYXS - TradingView
Pyxis Oncology (PYXS) Projected to Release Quarterly Earnings on Thursday - MarketBeat
Pyxis Oncology (NASDAQ:PYXS) Raised to Strong-Buy at Wells Fargo & Company - MarketBeat
PYXS Initiates Coverage On Wells Fargo -- Rating Set to Overweig - GuruFocus
Wells Fargo initiates Pyxis Oncology stock with overweight rating By Investing.com - Investing.com South Africa
Wells Fargo Initiates Pyxis Oncology at Overweight With $12 Price Target - marketscreener.com
Pyxis Oncology (PYXS) Slides 7.67% as Biotech Momentum Fades, Testing Key Support ZoneSuperTrend - vinanet.vn
PYXS|Pyxis Oncology Inc|Price:2.910|Chg%:+0.300 - TradingKey
Pyxis Oncology Inc (PYXS) Balance Sheet - TradingKey
Pyxis Oncology Inc (PYXS) 財務データ
収益
当期純利益
現金流量
EPS
0.86%
0.31%
大文字化:
|
ボリューム (24 時間):